BR112022004699A2 - Vs-6063 em combinação com ch5126766 para o tratamento de câncer - Google Patents

Vs-6063 em combinação com ch5126766 para o tratamento de câncer

Info

Publication number
BR112022004699A2
BR112022004699A2 BR112022004699A BR112022004699A BR112022004699A2 BR 112022004699 A2 BR112022004699 A2 BR 112022004699A2 BR 112022004699 A BR112022004699 A BR 112022004699A BR 112022004699 A BR112022004699 A BR 112022004699A BR 112022004699 A2 BR112022004699 A2 BR 112022004699A2
Authority
BR
Brazil
Prior art keywords
combination
cancer treatment
cancer
treatment
inhibitor
Prior art date
Application number
BR112022004699A
Other languages
English (en)
Inventor
Udai Banerji
Original Assignee
The Institute Of Cancer Res Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Res Royal Cancer Hospital filed Critical The Institute Of Cancer Res Royal Cancer Hospital
Publication of BR112022004699A2 publication Critical patent/BR112022004699A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

vs-6063 em combinação com ch5126766 para o tratamento de câncer. essa invenção está relacionada aos métodos que compreendem a administração de um inibidor de fak (por exemplo, vs-6063) em combinação com um inibidor duplo de raf/mek (por exemplo, ch5126766) que são úteis no tratamento de crescimento celular anormal, por exemplo, câncer, em um indivíduo como, por exemplo, humanos.
BR112022004699A 2019-09-13 2020-09-11 Vs-6063 em combinação com ch5126766 para o tratamento de câncer BR112022004699A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
PCT/EP2020/075455 WO2021048339A1 (en) 2019-09-13 2020-09-11 Vs-6063 in combination with ch5126766 for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022004699A2 true BR112022004699A2 (pt) 2022-06-14

Family

ID=67988988

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004699A BR112022004699A2 (pt) 2019-09-13 2020-09-11 Vs-6063 em combinação com ch5126766 para o tratamento de câncer

Country Status (11)

Country Link
US (3) US11517573B2 (pt)
EP (1) EP4028010A1 (pt)
JP (2) JP2022547358A (pt)
KR (1) KR20220078606A (pt)
CN (1) CN114630667A (pt)
AU (1) AU2020344829A1 (pt)
BR (1) BR112022004699A2 (pt)
CA (1) CA3152805A1 (pt)
MX (1) MX2022003063A (pt)
TW (1) TW202114677A (pt)
WO (3) WO2021047783A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021098679A1 (zh) * 2019-11-18 2021-05-27 应世生物科技(南京)有限公司 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
IL299789A (en) * 2020-07-13 2023-03-01 Verastem Inc Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapy
CN118103040A (zh) * 2021-07-27 2024-05-28 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
IL312248A (en) * 2021-10-28 2024-06-01 Verastem Inc Combined treatment for abnormal cell proliferation
EP4426304A1 (en) * 2021-11-02 2024-09-11 Verastem, Inc. Methods of treating abnormal cell growth
TW202329967A (zh) * 2022-01-21 2023-08-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
US20110086837A1 (en) 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
JP6061856B2 (ja) 2011-09-05 2017-01-18 中外製薬株式会社 クマリン誘導体の製造方法
WO2013170066A1 (en) 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for the treatment of cancer
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
IN2015DN02667A (pt) 2012-10-12 2015-09-04 Glaxosmithkline Llc
CN115708827A (zh) * 2014-01-09 2023-02-24 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法
JP2017505321A (ja) 2014-02-07 2017-02-16 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 異常な細胞成長を処置するための方法および組成物
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
JP7356414B2 (ja) * 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Also Published As

Publication number Publication date
WO2021047798A1 (en) 2021-03-18
CA3152805A1 (en) 2021-03-18
MX2022003063A (es) 2022-06-14
US20230277535A1 (en) 2023-09-07
EP4028010A1 (en) 2022-07-20
AU2020344829A1 (en) 2022-03-03
WO2021047783A1 (en) 2021-03-18
JP2022172480A (ja) 2022-11-17
US11517573B2 (en) 2022-12-06
US20220031698A1 (en) 2022-02-03
KR20220078606A (ko) 2022-06-10
JP2022547358A (ja) 2022-11-14
WO2021048339A1 (en) 2021-03-18
TW202114677A (zh) 2021-04-16
CN114630667A (zh) 2022-06-14
US20240197731A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
BR112018070161A2 (pt) moduladores de receptores de estrogênio
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112016029318A2 (pt) tratamento de mielomas
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
CR20140422A (es) Composiciones de enzima digestiva estable
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
WO2018039475A8 (en) Use of pridopidine for treating dystonias
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CO2021008997A2 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017008496A2 (pt) compostos para uso em tratamento antelmíntico
BR112019005886A2 (pt) tratamento com água de material lipídico